Antipsychotic News and Research

RSS

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Elan Corporation, plc today reported its fourth quarter and full-year 2009 financial results and provides financial guidance for 2010.

10 Feb 2010

Study: Schizophrenia patients may experience beneficial brain changes in response to exercise

Potentially beneficial brain changes (an increase in the volume of an area known as the hippocampus) occur in response to exercise both in patients with schizophrenia and healthy controls, according to a report in the February issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

1 Feb 2010

Consistent pattern of cognitive deficits during childhood leads to adult schizophrenia

Years before adults develop schizophrenia, there is a pattern of cognitive difficulties they experience as children, including problems with verbal reasoning, working memory, attention and processing speed.

22 Jan 2010

Tel Aviv University finds estrogen may protect women from psychosis

Many American women are prescribed estrogen to combat the negative effects of menopause, such as bone loss and mood swings. Now, new evidence from a Tel Aviv University study suggests that hormone replacement therapy might also protect them ― and younger women ― from schizophrenia as well.

21 Jan 2010

Majority of doctors appear to ignore FDA warning to screen high-risk medications

A new study concludes that many doctors appear to have largely ignored a Food and Drug Administration warning to screen users of new antipsychotic drugs for high blood sugar and cholesterol, which poses risks to their health and raises questions about the efficacy of warning protocols in general.

13 Jan 2010

Prescribing culture of antipsychotic medications in nursing homes examined

Older adults newly admitted to nursing homes with high rates of antipsychotic prescribing in the previous year are more likely to receive antipsychotic agents, according to a report in the January 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. Of these treated patients, some had no identified clinical indication for this therapy.

12 Jan 2010

Atypical antipsychotic use for treating elderly patients with dementia decreases

The use of atypical antipsychotics to treat elderly patients with dementia appears to have decreased following a 2005 Food and Drug Administration (FDA) advisory regarding the risks of these medications in this population, according to a report in the January 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

12 Jan 2010

EnVivo Pharmaceuticals announces initiation and dosing of patients in Phase 2b study of EVP-6124

EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase 2b study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with schizophrenia. EnVivo is conducting the multi-center, dose ranging, placebo controlled, three-month study in the U.S. and Europe.

6 Jan 2010

Study shows increasing number of U.S. adults are taking antidepressants and antipsychotic medications

An increasing number of U.S. adults are being prescribed combinations of antidepressants and antipsychotic medications, according to a report in the January issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

5 Jan 2010

Majority of Medicaid patients on antipsychotic drugs do not undergo metabolic tests, says study

Despite government warnings and professional recommendations about diabetes risks associated with second-generation antipsychotic drugs, fewer than one-third of Medicaid patients who are treated with these medications undergo tests of blood glucose or lipid levels, according to a report in the January issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

5 Jan 2010

DSPA submits lurasidone NDA to the FDA

Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lurasidone, an investigational atypical antipsychotic agent for the treatment of schizophrenia. The application, submitted on December 30, 2009, includes data from more than 40 clinical studies involving more than 2,500 lurasidone-treated patients.

4 Jan 2010

First animal model for studying schizophrenia

Scientists have created what appears to be a schizophrenic mouse by reducing the inhibition of brain cells involved in complex reasoning and decisions about appropriate social behavior.

29 Dec 2009

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Intra-Cellular Therapies, Inc. (ITI) announced at a recent conference on neuropsychiatric diseases the results from a recently completed Phase I clinical study demonstrating ITI-007, the Company's lead antipsychotic drug, interacts with important targets in the living human brain. These key targets are critical to drug action in many neuropsychiatric and related disorders.

21 Dec 2009

Antidepressants may play a key role in improving adolescents’ mental health

Suicidal adolescents who were prescribed an antidepressant medication during inpatient psychiatric hospital treatment were 85 percent less likely than others to be readmitted within a month after discharge, a new study found.

18 Dec 2009

ZYPREXA RELPREVV approved by FDA

The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company announced today.

14 Dec 2009

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week.

10 Dec 2009

Antiepileptic drugs may have a possible protective effect against seizure disorders

Despite government warnings about an increased risk of suicidal thoughts and actions while taking antiepileptic drugs, these medications do not appear to be associated with increased risk of suicide attempts in individuals with bipolar disorder, and may have a possible protective effect, according to a report in the December issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Dec 2009

Janssen-Cilag submits MAA to the European Medicines Agency for paliperidone palmitate

Elan Drug Technologies, a business unit of Elan Corporation, plc announced that Janssen-Cilag has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for paliperidone palmitate for the treatment of Schizophrenia.

4 Dec 2009

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

The U.S. Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old.

4 Dec 2009

FDA approves once-daily SEROQUEL XR Extended Release Tablets

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment to antidepressants in adults with Major Depressive Disorder (MDD).

4 Dec 2009

Antipsychotic News and Research

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Study: Schizophrenia patients may experience beneficial brain changes in response to exercise

Consistent pattern of cognitive deficits during childhood leads to adult schizophrenia

Tel Aviv University finds estrogen may protect women from psychosis

Majority of doctors appear to ignore FDA warning to screen high-risk medications

Prescribing culture of antipsychotic medications in nursing homes examined

Atypical antipsychotic use for treating elderly patients with dementia decreases

EnVivo Pharmaceuticals announces initiation and dosing of patients in Phase 2b study of EVP-6124

Study shows increasing number of U.S. adults are taking antidepressants and antipsychotic medications

Majority of Medicaid patients on antipsychotic drugs do not undergo metabolic tests, says study

DSPA submits lurasidone NDA to the FDA

First animal model for studying schizophrenia

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Antidepressants may play a key role in improving adolescents’ mental health

ZYPREXA RELPREVV approved by FDA

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Antiepileptic drugs may have a possible protective effect against seizure disorders

Janssen-Cilag submits MAA to the European Medicines Agency for paliperidone palmitate

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

FDA approves once-daily SEROQUEL XR Extended Release Tablets

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News